Huya CEO Mireille Gingras On Partnering To Develop Chinese Compounds In The West: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
San Diego-based Huya Bioscience partners with Chinese research institutions and companies to identify preclinical and clinical-stage compounds, including traditional Chinese medicines to license for ex-China development. CEO Mireille Gingras recently spoke with PharmAsia News about Huya's partnership efforts in China. Prior to founding Huya, Gingras was founder and chief operating officer of MIR3, a software company developing online treatment programs for neuro-addictive diseases.
You may also be interested in...
INTERVIEW: Chipscreen CEO Bets Big On Chinese Innovation
When initial funding burned through and co-founders bailed out, Chipscreen CEO Lu Xianping faced the biggest challenge of his career. A firm belief in scientific evidence and an unwavering confidence in China-originated innovation helped him launch chidamide, a true made in China drug for a rare blood cancer, Lu told PharmAsia News in an exclusive interview.
Fresh Off Schering-Plough Deal, Huya Signs Pact With Beijing Institute To Open Bridge To Global Markets
BEIJING - Huya Bioscience International has signed a partnership agreement with the Beijing Institute of Materia Medica on joint development of innovative drugs that ultimately could help the institute penetrate the American and European markets, according to a senior Huya executive
Fresh Off Schering-Plough Deal, Huya Signs Pact With Beijing Institute To Open Bridge To Global Markets
BEIJING - Huya Bioscience International has signed a partnership agreement with the Beijing Institute of Materia Medica on joint development of innovative drugs that ultimately could help the institute penetrate the American and European markets, according to a senior Huya executive